Navigation Links
Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
Date:10/6/2008

expert in translational medicine, and a pioneer in the therapeutic use of RNAi, particularly through the development of innovative delivery tools. The Lieberman laboratory at Harvard was the first to demonstrate that RNAi could be used to treat disease in an animal model. Dr. Lieberman and her colleagues are currently working to harness RNAi for use against HIV and other viruses and they have developed novel strategies for cell-specific targeting of small interfering RNAs to confer in vivo protection from viral disease. In related work, Dr. Lieberman's laboratory is also working in the emerging field of miRNAs by developing their potential as diagnostic and therapeutic tools.

Professor Patrice Courvalin, M.D., is head of the Antibacterial Agents Unit at the Institut Pasteur, Paris, France, where he directs the French National Reference Center for Antibiotics. He is an internationally recognized expert in the genetics and biochemistry of antibiotic resistance and in the transfer and heterologous expression of genetic information. He received master's degrees in sciences and in human biology from the University of Sciences in Paris and his doctorate in medical sciences from the Medical School in Paris. His research has led to a revision of the dogma describing natural dissemination of genes. In particular, he and his colleagues demonstrated that a wide variety of bacteria can promiscuously exchange genetic material and they proved that conjugation could account for dissemination of genes between phylogenetically remote bacterial genera. Because of his long-term interest in horizontal gene transfer among bacteria, Dr. Courvalin has been a thought leader in the area of using bacteria as intracellular vectors for delivery of DNA or proteins into mammalian cells. His laboratory was the first to describe the combination of invasin and listeriolysin to enable Escherichia coli as a gene therapy tool.

About Cequent Pharmaceuticals, Inc.

SOURCE Cequent Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
2. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
3. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
4. Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs
5. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
6. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
7. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Thermo Fisher Scientific to Present at Investor Conferences
10. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
11. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... April 16, 2015 Cambridge ... solutions driven by Semantic Web technology, and ... information and services for the academic and scientific, ... its joint solution ‘Smart Data Lake for Clinical ... for the 2015 Bio-IT ‘Best of Show’ Award. ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... TORONTO , April 16, 2015 /PRNewswire/ - Portage ... PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce ... Investor Show on April 25, 2015 to be held ... Dr. Gregory Bailey and Mr. James ... overview and an update on the key programs at ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., ... of therapeutic antibodies, today announced the advancement ... program into IND-enabling studies. The Company,s anti-IL-36R ... treatment for generalized pustular psoriasis (GPP), an ... medical need. ANB019 is wholly owned within AnaptysBio,s ...
Breaking Biology Technology:Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2
... a long-planned departure from its traditional focus, high-end computer ... U.S. Army for development of two different products. , ... it has secured $2.2 million in federal contracts for ... the Armys Research, Development and Engineering Command (CERDEC) to ...
... Inc. for the quarter ended March 31 rose to $142.5 ... company earned the same quarter of 2004. , ,Profit for ... even $150 million, compared to $78.3 million a year ago. ... more than $10 per share Tuesday and Wednesday from Monday's ...
... Milwaukee Merge eFilm , the Milwaukee-based ... Inc., continued to build momentum leading into its proposed ... net sales of just more than $10.5 million in ... first quarter 2004, after a 19 percent year-over-year jump ...
Cached Biology Technology:SLE of Eau Claire lands $2.2 million in federal contracts 2SLE of Eau Claire lands $2.2 million in federal contracts 3Merge eFilm earnings jump precedes planned merger 2Merge eFilm earnings jump precedes planned merger 3
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... controlled trial of fish oil given intravenously to patients ... exchange, reduces inflammatory chemicals and results in a shorter ... open access journal Critical Care investigated the ... solution for patients with sepsis, finding a significant series ...
... 1. Prescribed Opioids Associated with Significant Risk for ... oxycodone, have increased significantly over the past decade. As ... common, the deaths associated with opioids increase. Opioid overdose ... Researchers sought to determine the rate of opioid overdose ...
... MIT and Harvard Medical School have built targeted nanoparticles ... medicine, an advance that potentially provides an alternative to ... The particles, dubbed "nanoburrs" because they are coated with ... target proteins, can be designed to release their drug ...
Cached Biology News:Annals of Internal Medicine tip sheet for Jan. 19, 2010, issue 2Annals of Internal Medicine tip sheet for Jan. 19, 2010, issue 3New nanoparticles target cardiovascular disease 2
This spacer is required to use the Miniature FRENCH Pressure Cell (FA-003) with the Laboratory Press....
... (M-MLV RT) is an RNA-dependent DNA polymerase that ... messenger RNA templates (>5kb). The enzyme is a ... consists of a single subunit with a molecular ... M-MLV RT is weaker than the commonly used ...
... of Cell Cultures (ECACC) in conjunction with ... West of England, Bristol, UK, have produced ... of HER2, oestrogen and progresterone receptor assays. ... of formalin fixed, breast cancer cell lines; ...
... highly potent TURBO DNase (patent pending) in the ... in DNA removal capabilities. TURBO DNase is a ... much more efficient than wild type DNase I ... TURBO DNase binds DNA substrates 6-fold more tightly ...
Biology Products: